172 completed, 48 terminated, 40 recruiting, 29 unknown. 322 Phase 1, 112 Phase 2.
Follow Head and Neck Cancer: new trials by email Literature Review of Head and Neck Cancer trials Research Report on Head and Neck Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-04 | 2026-10-30 |
| Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia Metformin, Naproxen Sodium - Fanconi Anemia, Head and Neck Cancer | Phase 1 | Recruiting | Rockefeller University | 80 | 2026-10-14 | 2026-10-28 |
| Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma Panitumumab-IRDye800, [18F]NOTA-ABY-030 - HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2026-10-01 | 2026-10-19 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-10-01 | 2026-10-29 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| Using Silverlon® for Head and Neck Patients With Tracheostomies Silverlon® - Head and Neck Cancer, Radiation Dermatitis Acute | Phase 1 | Recruiting | State University of New York - Upstate Medical University | 10 | 2026-08-30 | 2026-10-05 |
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies camrelizumab with famitinib - Head and Neck Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 40 | 2026-07-01 | 2026-06-23 |
| Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors NCP-CD47 siRNA intratumorally injection - Solid Tumor Cancer, Metastases | Phase 1 | Not yet recruiting | West China Hospital | 9 | 2026-05-30 | 2026-05-13 |
| A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors CRPA1A2 - Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer | Phase 1 | Not yet recruiting | Corregene Biotechnology Co., Ltd | 192 | 2026-05-29 | 2026-05-13 |
| Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) Pedmark® STS - Solid Tumor Malignancies, Testicular Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 25 | 2026-05-18 | 2026-06-18 |
| A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine - Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Zelluna Immunotherapy AS | 9 | 2026-05-11 | 2026-09-04 |
| A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC EPI-326 - Epidermal Growth Factor, Epidermal Growth Factor Receptor | Phase 1 | Recruiting | EpiBiologics | 110 | 2026-03-31 | 2026-10-14 |
| Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer Pembrolizumab, Definity, Ultrasound-Induced Microbubble Cavitation - Head and Neck Cancer, Head and Neck Small Cell Carcinoma | Phase 1 | Recruiting | Thomas Jefferson University | 6 | 2026-03-18 | 2026-10-28 |
| Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Decitabine, Nivolumab - Head and Neck Cancer, Head and Neck Neoplasms | Phase 1 | Withdrawn | Case Comprehensive Cancer Center | 2026-01-01 | 2026-06-22 | |
| Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK) Fludarabine, Cyclophosphamide - Head and Neck Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 33 | 2025-12-19 | 2026-10-05 |
| Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors OCT-598, Docetaxel - Solid Tumor, Breast Cancer | Phase 1 | Recruiting | Oscotec Inc. | 51 | 2025-12-18 | 2026-01-22 |
| Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma Proton therapy, Pembrolizumab - Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Cincinnati | 40 | 2025-10-08 | 2026-07-01 |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) - Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 150 | 2025-08-22 | 2026-09-17 |
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors PF-08046876, Pembrolizumab, Cisplatin - Advanced/Metastatic Solid Tumors, Bladder Cancer | Phase 1 | Recruiting | Pfizer | 540 | 2025-08-20 | 2026-10-13 |
Showing 20 of 322. Sign in to see all of them.
Head and Neck Neoplasms (322) · Squamous Cell Carcinoma of Head and Neck (87) · Carcinoma, Non-Small-Cell Lung (66) · Colorectal Neoplasms (59) · Breast Neoplasms (57) · Ovarian Neoplasms (54) · Lung Neoplasms (53) · Pancreatic Neoplasms (46) · Melanoma (43) · Neoplasms (39) · Stomach Neoplasms (35) · Esophageal Neoplasms (32) · Neoplasm Metastasis (30) · Prostatic Neoplasms (28) · Sarcoma (24)
Neoplasms by Site (321) · Neoplasms (283) · Neoplasms by Histologic Type (183) · Neoplasms, Glandular and Epithelial (161) · Carcinoma (144) · Respiratory Tract Diseases (122) · Respiratory Tract Neoplasms (119) · Digestive System Diseases (104) · Thoracic Neoplasms (103) · Lung Diseases (102) · Digestive System Neoplasms (98) · Gastrointestinal Diseases (97) · Skin and Connective Tissue Diseases (91) · Urogenital Diseases (90) · Skin Diseases (89)
Cisplatin (44) · Radiotherapy (38) · pembrolizumab (31) · Cetuximab (21) · Docetaxel (18) · Paclitaxel (17) · Carboplatin (15) · Fluorouracil (12) · Nivolumab (12) · Cyclophosphamide (10) · Radiotherapy, Intensity-Modulated (10) · Erlotinib Hydrochloride (8) · Gemcitabine (8) · fludarabine (8) · Pemetrexed (7)
National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (11) · Memorial Sloan Kettering Cancer Center (11) · Incyte Corporation (5) · Case Comprehensive Cancer Center (4) · Celldex Therapeutics (4) · Dana-Farber Cancer Institute (4) · Masonic Cancer Center, University of Minnesota (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Erasmus Medical Center (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Genmab (3) · Pfizer (3) · Providence Health & Services (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3)
United States (229) · United Kingdom (22) · Canada (18) · Spain (17) · China (15) · Belgium (13) · Netherlands (13) · France (12) · South Korea (12) · Australia (9) · Germany (8) · Italy (8) · Taiwan (7) · Japan (4) · Israel (3)
David Hong, MD (3) · Ari Rosenberg, MD (2) · Arkadiusz Dudek, MD (2) · Carter Van Waes, MD, PhD (2) · David Pfister, MD (2) · Eben Rosenthal, MD (2) · Farrokh Dehdashti, M.D. (2) · Hassan Arshad, MD (2) · Herbert K. Lyerly, MD (2) · Howard Safran, MD (2) · John Rasmussen, PhD (2)
PMID 15033677, PMID 15240677, PMID 15542583, PMID 16116597, PMID 17538162, PMID 17538163, PMID 17985341, PMID 18276844, PMID 19060587, PMID 19097774, PMID 19372041, PMID 19540060, PMID 19596976, PMID 19602035, PMID 19671873, PMID 19735988, PMID 19879702, PMID 20145168, PMID 20407240, PMID 20605352, PMID 21300462, PMID 21367608, PMID 22658127, PMID 22847809, PMID 22847995, PMID 22989664, PMID 23160470, PMID 23228990, PMID 23635996, PMID 24727329, PMID 24953566, PMID 25423330, PMID 25899782, PMID 26181029, PMID 26688544, PMID 27226436, PMID 27435312, PMID 27489285, PMID 28352657, PMID 28397821, PMID 28645940, PMID 28950289, PMID 29054476, PMID 29319049, PMID 29322091, PMID 29634946, PMID 29735994, PMID 29802087, PMID 29924973, PMID 31177991
2017 (4), P30CA043703 (4), P30CA006516 (3), U01CA062502 (2), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2023 (1), 2025 (1), 4UH3DE030431-02 (1), P01CA006294 (1), P30CA012197 (1), P30CA014520 (1), P30CA016672 (1)